Literature DB >> 27533158

Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening.

Imran S Haque1, Gabriel A Lazarin1, H Peter Kang1, Eric A Evans1, James D Goldberg1, Ronald J Wapner2.   

Abstract

IMPORTANCE: Screening for carrier status of a limited number of single-gene conditions is the current standard of prenatal care. Methods have become available allowing rapid expanded carrier screening for a substantial number of conditions.
OBJECTIVES: To quantify the modeled risk of recessive conditions identifiable by an expanded carrier screening panel in individuals of diverse racial and ethnic backgrounds and to compare the results with those from current screening recommendations. DESIGN, SETTING, AND PARTICIPANTS: Retrospective modeling analysis of results between January 1, 2012, and July 15, 2015, from expanded carrier screening in reproductive-aged individuals without known indication for specific genetic testing, primarily from the United States. Tests were offered by clinicians providing reproductive care. EXPOSURES: Individuals were tested for carrier status for up to 94 severe or profound conditions. MAIN OUTCOMES AND MEASURES: Risk was defined as the probability that a hypothetical fetus created from a random pairing of individuals (within or across 15 self-reported racial/ethnic categories; there were 11 categories with >5000 samples) would be homozygous or compound heterozygous for 2 mutations presumed to cause severe or profound disease. Severe conditions were defined as those that if left untreated cause intellectual disability or a substantially shortened lifespan; profound conditions were those causing both.
RESULTS: The study included 346,790 individuals. Among major US racial/ethnic categories, the calculated frequency of fetuses potentially affected by a profound or severe condition ranged from 94.5 per 100,000 (95% CI, 82.4-108.3 per 100,000) for Hispanic couples to 392.2 per 100,000 (95% CI, 366.3-420.2 per 100,000) for Ashkenazi Jewish couples. In most racial/ethnic categories, expanded carrier screening modeled more hypothetical fetuses at risk for severe or profound conditions than did screening based on current professional guidelines (Mann-Whitney P < .001). For Northern European couples, the 2 professional guidelines-based screening panels modeled 55.2 hypothetical fetuses affected per 100,000 (95% CI, 51.3-59.3 per 100,000) and the expanded carrier screening modeled 159.2 fetuses per 100,000 (95% CI, 150.4-168.6 per 100,000). Overall, relative to expanded carrier screening, guideline-based screening ranged from identification of 6% (95% CI, 4%-8%) of hypothetical fetuses affected for East Asian couples to 87% (95% CI, 84%-90%) for African or African American couples. CONCLUSIONS AND RELEVANCE: In a population of diverse races and ethnicities, expanded carrier screening may increase the detection of carrier status for a variety of potentially serious genetic conditions compared with current recommendations from professional societies. Prospective studies comparing current standard-of-care carrier screening with expanded carrier screening in at-risk populations are warranted before expanded screening is adopted.

Entities:  

Mesh:

Year:  2016        PMID: 27533158     DOI: 10.1001/jama.2016.11139

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  49 in total

1.  The "industrial" revolution in biomedical research: Data explosion and reproducibility crisis drive changes in lab workflows.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2020-01-27       Impact factor: 8.807

2.  Importance of complete phenotyping in prenatal whole exome sequencing.

Authors:  Mahmoud Aarabi; Olivia Sniezek; Huaiyang Jiang; Devereux N Saller; Daniel Bellissimo; Svetlana A Yatsenko; Aleksandar Rajkovic
Journal:  Hum Genet       Date:  2018-02-01       Impact factor: 4.132

Review 3.  Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening.

Authors:  Kathryn J Gray; Louise E Wilkins-Haug
Journal:  Pediatr Radiol       Date:  2018-03-17

Review 4.  Obstetric management, tests, and technologies that impact childhood development.

Authors:  Christopher M Novak; Ernest M Graham
Journal:  Dev Med Child Neurol       Date:  2019-01-28       Impact factor: 5.449

5.  Should Clinicians Leave "Expanded" Carrier Screening Decisions to Patients?

Authors:  Amanda Fakih; Kayte Spector-Bagdady
Journal:  AMA J Ethics       Date:  2019-10-01

Review 6.  Expanded carrier screening: counseling and considerations.

Authors:  Teresa N Sparks
Journal:  Hum Genet       Date:  2019-11-02       Impact factor: 4.132

7.  Pregnant Women's Perspectives on Expanded Carrier Screening.

Authors:  Lauren Propst; Gwendolyn Connor; Megan Hinton; Tabitha Poorvu; Jeffrey Dungan
Journal:  J Genet Couns       Date:  2018-02-23       Impact factor: 2.537

8.  Associations of perceived norms with intentions to learn genomic sequencing results: Roles for attitudes and ambivalence.

Authors:  Allecia E Reid; Jennifer M Taber; Rebecca A Ferrer; Barbara B Biesecker; Katie L Lewis; Leslie G Biesecker; William M P Klein
Journal:  Health Psychol       Date:  2018-05-10       Impact factor: 4.267

9.  The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing.

Authors:  Yanming Feng; Xiaoyan Ge; Linyan Meng; Jennifer Scull; Jianli Li; Xia Tian; Tao Zhang; Weihong Jin; Hanyin Cheng; Xia Wang; Mari Tokita; Pengfei Liu; Hui Mei; Yue Wang; Fangyuan Li; Eric S Schmitt; Wei V Zhang; Donna Muzny; Shu Wen; Zhao Chen; Yaping Yang; Arthur L Beaudet; Xiaoming Liu; Christine M Eng; Fan Xia; Lee-Jun Wong; Jinglan Zhang
Journal:  Genet Med       Date:  2017-01-26       Impact factor: 8.822

10.  CNVs cause autosomal recessive genetic diseases with or without involvement of SNV/indels.

Authors:  Bo Yuan; Lei Wang; Pengfei Liu; Chad Shaw; Hongzheng Dai; Lance Cooper; Wenmiao Zhu; Stephanie A Anderson; Linyan Meng; Xia Wang; Yue Wang; Fan Xia; Rui Xiao; Alicia Braxton; Sandra Peacock; Eric Schmitt; Patricia A Ward; Francesco Vetrini; Weimin He; Theodore Chiang; Donna Muzny; Richard A Gibbs; Arthur L Beaudet; Amy M Breman; Janice Smith; Sau Wai Cheung; Carlos A Bacino; Christine M Eng; Yaping Yang; James R Lupski; Weimin Bi
Journal:  Genet Med       Date:  2020-06-24       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.